Hiroaki Hagiwara

This inventor holds 11 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroaki Hagiwara. Retrieved from https://idiyas.com/inventor/hiroaki-hagiwara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 11.7

ph-index = 6

Forward Citations = 109(Granted Patents)

Company Filing History:

11 out of 530

Eisai R&d Management Co., Ltd.

patents

Years Active: 2009-2016

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9453000 - Polycyclic compound (2016-09-27),

2. 8048878 - Two cyclic cinnamide compound (2011-11-01),

3. 8008293 - Bicyclic oxomorpholine derivative (2011-08-30),

4. 7973033 - Multi-cyclic cinnamide derivatives (2011-07-05),

5. 7935815 - Imidazoyl pyridine compounds and salts thereof (2011-05-03),

6. 7897632 - Multi-cyclic cinnamide derivatives (2011-03-01),

7. 7880009 - Cinnamide compound (2011-02-01),

8. 7713993 - Multi-cycle cinnamide derivatives (2010-05-11),

9. 7687640 - Cinnamide compound (2010-03-30),

10. 7667041 - Cinnamide compound (2010-02-23),

11. 7618960 - Morpholine type cinnamide compound (2009-11-17),

Title: Hiroaki Hagiwara: Innovator in Pharmaceutical Compounds

Introduction

Hiroaki Hagiwara is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target neurodegenerative diseases. With a total of 11 patents to his name, Hagiwara's work is recognized for its potential therapeutic applications.

Latest Patents

Hagiwara's latest patents include a polycyclic compound that serves as a therapeutic or prophylactic agent for diseases induced by Aβ. This compound is characterized by a formula that includes an imidazolyl group and a phenyl group, both of which may be substituted with various alkyl and alkoxy groups. Another notable invention is a novel two cyclic cinnamide compound, which has shown effectiveness in reducing Aβ40 and Aβ42 production. This compound is particularly useful as a therapeutic agent for neurodegenerative diseases such as Alzheimer's disease and Down's syndrome.

Career Highlights

Hagiwara is currently employed at Eisai R&D Management Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the understanding and treatment of neurodegenerative conditions.

Collaborations

Hagiwara has collaborated with notable colleagues, including Teiji Kimura and Koki Kawano. Their combined expertise has contributed to the successful development of various pharmaceutical compounds.

Conclusion

Hiroaki Hagiwara's contributions to the field of pharmaceuticals highlight his role as a key innovator in developing treatments for neurodegenerative diseases. His ongoing research and patent portfolio reflect his commitment to improving health outcomes through innovative solutions.

Profile summary based on public USPTO records.